

## Quantel Medical receives FDA Approval for the VITRA 2<sup>®</sup> laser for Retinal Photocoagulation



COURNON D'AUVERGNE, France – December 06<sup>th</sup>, 2019 – **Quantel Medical** announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the **Vitra 2<sup>®</sup> photocoagulator**.

**Vitra 2<sup>®</sup>** includes all the key elements that have made the success of the Vitra photocoagulator such as reliability, compactness and versatility. It also features a wide a range of improvements and new functionalities:

### Technology:

**Vitra 2<sup>®</sup>** features a new generation of optimized laser cavity with an increased max power level. It is also now compatible with SingleSpot and MultiSpot technologies.

### All-new clinically oriented software:

**Vitra 2<sup>®</sup>** features an easy to use clinically oriented software interface simplifying the treatment procedures and the doctors' workflow thanks to printable treatment reports.

### Wide range of delivery systems:

**Vitra 2<sup>®</sup>** is compatible with Haag Streit and Zeiss types slit lamps, with Quantel Medical YAG and YAG/SLT lasers and can be connected to a wide range of delivery systems (operating Microscopes, laser indirect ophthalmoscopes and laser probes).

*“After a successful career spanning more than 13 years and with more than 3000 units sold worldwide, Quantel Medical is proud to announce the renewal of its 532nm flagship Vitra photocoagulator” said Jean-Marc Gendre, CEO Quantel Medical. “We are very excited to bring our new 532nm laser to ophthalmologists and their patients. Thanks to its flexibility and its ease of use, we are sure that more and more surgeons will embrace the MultiSpot technology delivery mode and its associated treatments benefits for retinal photocoagulation.”*

Already launched in Europe in 2018, the **Vitra 2<sup>®</sup>** laser has already met its market across the various countries where it is commercialized.

## About Quantel Medical

Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases.

Quantel Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions and a comprehensive product portfolio of diagnostic ultrasound, surgical lasers and a range of disposable products for ophthalmologists.

These products are available through direct sales operations in the U.S., France and Poland, and through 80 independent distributors in over 110 countries. Quantel Medical is a division of Lumibird (LBIRD - FR0000038242 / Paris), a world-wide leader in the development of solid state lasers for scientific and industrial applications.

Company contact:

Jan-Philippe Heydel: [Jan-Philippe.Heydel@quantel-medical.fr](mailto:Jan-Philippe.Heydel@quantel-medical.fr)

Media contact:

Stephanie Belot: [Stephanie.Belot@quantel-medical.fr](mailto:Stephanie.Belot@quantel-medical.fr) - [www.quantel-medical.com](http://www.quantel-medical.com)